Sodium-glucose linked transporter 2 inhibitors reduce serum uric acid in type 2 diabetic mellitus patients with early nephropathy

doi:10.16138/j.1673-6087.2025.05.04

Abstract

Abstract:

Objective To explore the reducing serum uric acid (SUA) effects of dapagliflozin, a sodium-glucose linked transporter 2 (SGLT2) inhibitor in patients with type 2 diabetes mellitus (T2DM) with early nephropathy and hyperuricemia. Methods Sixty-five patients with early T2 diabetic nephropathy and hyperuricemia admitted to our hospital from June 2020 to June 2023 were enrolled. After 4 weeks of treatment with dapagliflozin, a paired-sample T-test was used to analyze the changes in SUA, glycosylated hemoglobin (HbA_1c), fasting plasma glucose (FPG), serum creatinine (SCr), total cholesterol (TC), triglyceride (TG), urine albumin-to-creatinine ratio (UACR), body weight and other clinical indexes. Linear regression analysis was performed to determine the relationship between the changes of SUA before (baseline) and after treatment. Results In this group of 65 T2DM patients with early nephropathy and hyperuricemia, 4 weeks of dapagliflozin reduced SUA [(436.1±39.5)vs (392.2±32.2) μmol/L,P<0.001], FPG [(7.66±2.23)vs (6.40±1.06) mmol/L,P<0.001], UACR [(211.3±73.2)vs (177.8±88.3) mg/g,P=0.005], and body weight [(63.1±9.7)vs (62.7±9.3) kg,P=0.038] significantly. Systolic blood pressure, diastolic blood pressure, HbA_1c, TC, TG, SCr, estimated glomerular filtration rate (eGFR), and other levels were not changed (P>0.05). Linear regression analysis showed that the decreased levels of SUA positively correlated with the baseline levels of SUA (β=0.634,R²=0.401,P<0.001). Conclusions SGLT2 could effectively decrease blood glucose levels in patients with early T2DM nephropathy, and significantly reduce serum uric acid and urinary microalbumin.

Key words: Serum uric acid, Diabetic nephropathy, Sodium-glucose linked transporter 2 inhibitors

CLC Number:

R587.1
R692

WU Qianqian, GUO Jie, WANG Yifan, LIU Li, WANG Feng. Sodium-glucose linked transporter 2 inhibitors reduce serum uric acid in type 2 diabetic mellitus patients with early nephropathy[J]. Journal of Internal Medicine Concepts & Practice, 2025, 20(05): 371-375.

Figures/Tables 2

References 21

[1]	Concepción M, Quiroz J, Suarez J, et al. Novel biomarkers for the diagnosis of diabetic nephropathy[J]. Caspian J Intern Med, 2024, 15(3): 382-391.
[2]	Sridhar VS, Cosentino F, Dagogo-Jack S, et al. Effects of ertugliflozin on uric acid and gout-related outcomes in persons with type 2 diabetes and cardiovascular disease: post hoc analyses from VERTIS CV[J]. Diabetes Obes Metab, 2024, 26(11): 5336-5346. doi: 10.1111/dom.15895
[3]	Shaffner J, Chen B, Malhotra DK, et al. Therapeutic targeting of SGLT2: a new era in the treatment of diabetes and diabetic kidney disease[J]. Front Endocrinol (Lausanne), 2021, 12: 749010. doi: 10.3389/fendo.2021.749010
[4]	Liu B, Wang Y, Zhang Y, et al. Mechanisms of protective effects of SGLT2 inhibitors in cardiovascular disease and renal dysfunction[J]. Curr Top Med Chem, 2019, 19(20): 1818-1849. doi: 10.2174/1568026619666190828161409
[5]	O'Hara DV, Lam CSP, McMurray JJV, et al. Applications of SGLT2 inhibitors beyond glycaemic control[J]. Nat Rev Nephrol, 2024, 20(8): 513-529. doi: 10.1038/s41581-024-00836-y
[6]	中华医学会糖尿病学分会微血管并发症学组. 糖尿病肾病防治专家共识（2014年版）[J]. 中华糖尿病杂志, 2014, 6(11): 792-801.
	Chinese Diabetes Society Microvascular Complications Group. Expert consensus on prevention and treatment of diabetic kidney disease (2014 edition)[J]. Chin J Diabetes, 2014, 6(11): 792-801.
[7]	中国医师协会肾脏内科医师分会. 中国肾脏疾病高尿酸血症诊治的实践指南（2017版）[J]. 中华医学杂志, 2017, 97(25): 1927-1936.
	Chinese Nephrologist Association. Practice guideline for the diagnosis and treatment of hyperuricemia in kidney disease in China (2017 edition)[J]. Natl Med J China, 2017, 97(25): 1927-1936.
[8]	Doehner W, Anker SD, Butler J, et al. Uric acid and SGLT2 inhibition with empagliflozin in heart failure with preserved ejection fraction: the EMPEROR-preserved trial[J]. JACC Heart Fail, 2024, 12(12): 2057-2070. doi: 10.1016/j.jchf.2024.08.020
[9]	McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction[J]. N Engl J Med, 2019, 381(21): 1995-2008. doi: 10.1056/NEJMoa1911303
[10]	Suijk DLS, van Baar MJB, van Bommel EJM, et al. SGLT2 inhibition and uric acid excretion in patients with type 2 diabetes and normal kidney function[J]. Clin J Am Soc Nephrol, 2022, 17(5): 663-671. doi: 10.2215/CJN.11480821
[11]	Vallon V, Verma S. Effects of SGLT2 inhibitors on kidney and cardiovascular function[J]. Annu Rev Physiol, 2021, 83: 503-528. doi: 10.1146/annurev-physiol-031620-095920
[12]	Liu P, Chen Y, Wang B, et al. Allopurinol treatment improves renal function in patients with type 2 diabetes and asymptomatic hyperuricemia: 3-year randomized parallel-controlled study[J]. Clin Endocrinol (Oxf), 2015, 83(4): 475-482. doi: 10.1111/cen.12673
[13]	Novikov A, Fu Y, Huang W, et al. SGLT2 inhibition and renal urate excretion: role of luminal glucose, GLUT9, and URAT1[J]. Am J Physiol Renal Physiol, 2019, 316(1): F173-F185. doi: 10.1152/ajprenal.00462.2018
[14]	Toyama T, Neuen BL, Jun M, et al. Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and meta-analysis[J]. Diabetes Obes Metab, 2019, 21(5): 1237-1250. doi: 10.1111/dom.13648
[15]	Beal B, Schutte AE, Neuen BL. Blood pressure effects of SGLT2 inhibitors: mechanisms and clinical evidence in different populations[J]. Curr Hypertens Rep, 2023, 25(12): 429-435. doi: 10.1007/s11906-023-01281-1
[16]	Kelly MS, Lewis J, Huntsberry AM, et al. Efficacy and renal outcomes of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease[J]. Postgrad Med, 2019, 131(1): 31-42. doi: 10.1080/00325481.2019.1549459
[17]	Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes[J]. N Engl J Med, 2019, 380(4): 347-357. doi: 10.1056/NEJMoa1812389
[18]	Bailey CJ, Day C, Bellary S. Renal protection with SGLT2 inhibitors: effects in acute and chronic kidney disease[J]. Curr Diab Rep, 2022, 22(1): 39-52. doi: 10.1007/s11892-021-01442-z
[19]	Cheong AJY, Teo YN, Teo YH, et al. SGLT inhibitors on weight and body mass: a meta-analysis of 116 randomized-controlled trials[J]. Obesity (Silver Spring), 2022, 30(1): 117-128. doi: 10.1002/oby.23331
[20]	Ravindran S, Munusamy S. Renoprotective mechanisms of sodium-glucose co-transporter 2 (SGLT2) inhibitors against the progression of diabetic kidney disease[J]. J Cell Physiol, 2022, 237(2): 1182-1205. doi: 10.1002/jcp.30621
[21]	Lioudaki E, Joslin JR, Trachanatzi E, et al. The role of sodium-glucose co-transporter (SGLT)-2 inhibitors in heart failure management and implications for the kidneys[J]. Rev Cardiovasc Med, 2022, 23(3): 82. doi: 10.31083/j.rcm2303082

项目	治疗前	治疗后	∆_m	t/Z	P
∆_m=治疗后−治疗前均数; 1 mmHg=0.133 kPa。
收缩压（mmHg）	126.45±31.91	125.60±22.38	−0.85±37.05	0.18	0.854
舒张压（mmHg）	82.23±13.93	81.86±12.53	−3.69±17.21	0.17	0.863
体重（kg）	63.08±9.74	62.68±9.29	−0.40±1.50	2.12	0.038
SCr（μmol/L）	80.97±13.97	79.06±14.54	−1.91±17.13	0.90	0.373
eGFR[mL/(min·1.73m²)]	86.48±20.51	90.16±24.92	3.68±22.17	−1.34	0.185
尿素氮（mmol/L）	9.14±2.66	8.69±2.45	−0.45±2.88	1.27	0.209
SUA（μmol/L）	436.07±39.53	392.18±32.18	−43.89±15.04	23.53	<0.001
FBG（mmol/L）	7.66±2.23	6.40±1.06	−1.27±1.46	6.99	<0.001
HbA_1c（%）	7.51±1.22	7.34±0.91	−0.17±0.97	1.39	0.170
TC（mmol/L）	4.61±1.32	4.43±1.21	−0.19±1.91	0.79	0.433
TG（mmol/L）	1.68±1.01	1.81±1.10	0.13±1.54	0.68	0.491
UACR（mg/g）	211.31±73.21	177.83±88.28	−33.48±92.33	2.92	0.005